Brand profile · Biotechnology Research

BioSyngen

Hougang, North East Community Development Council-based BioSyngen operates in Biotechnology Research. Ownership is privately held; it publishes at biosyngen.com. It holds one address on record, all in Singapore. The record counts 19 people. Tagged cell Therapy, GMP Manufacturing and solid Tumor. One Singapore registration (UEN) is a confirmed match. Its latest round on record is Series unknown, US$78.2M. It is listed alongside five similar brands, mostly in Biotechnology Research.

LinkedIn

Profile live Privately Held Founded 2016 1 entity UEN 1 office country US$ 78.2M Series unknown
Registry verified · ACRA
Counted staff
19
self-reported band not used
Founded
2016
10 years
Legal entities
1
ACRA
Office countries
1
1 address
Funding rounds
1
Series unknown · Nov 2021 · US$ 78.2M
Company type
Privately Held
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 confirmed entity

Legal entities

BioSyngen: 1 registry entityBioSyngen is linked to 1 registry entity: BIOSYNGEN PTE. LTD. (UEN 201618108R, confirmed).BioSyngenBIOSYNGEN PTE. LTD.UEN 201618108RConfirmed · ACRA
Show as table
BIOSYNGEN PTE. LTD.UEN 201618108R
Confirmed matches1 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

Biosyngen is a cell therapy company focusing on unmet needs with technology targeting solid tumors and lymphoproliferative diseases. The company’s first-in-class products have entered into Phase I/II clinical trials for nasopharyngeal cancer (ODD and Fast-Track), lymphoproliferative disease and lung cancer. The company continues to enrich its pipeline with further IND submissions.

Biosyngen drives its international strategy from the global headquarter in Singapore, with its clinical center situated in Guangzhou, China. Leverages on the public-private biopharma ecosystem for the better cause.

Committed to giving cancer patients a better chance to survive, our pipeline is enriched, covering other major indications which are on track for regulatory registration.

Biosyngen seeks breakthrough in collaborations, particularly in translational R&D and clinical development. The company has positioned GMP cell therapy manufacturing facilities in two locations - in Singapore and Guangzhou covering global needs.

To quicken drug development from bench-to-bedside, a parallel effort in the form of the Translational Medicine Centre is set up. It is public-private-partnership connecting stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises and Venture Capital.

Follow us on LinkedIn. For more information, visit our website at www.biosyngen.com

Specialties

All 6 specialties
  • Cell Therapy
  • GMP Manufacturing
  • Solid Tumor
  • CAR-T
  • TCR-T
  • TIL

Locations

Singaporeprimary

Country footprint

Offices in 1 countryCountry footprint: 1 country, primary SG. Codes: SG.1 countryprimary SGSG
Show as table
Countries1
Primary countrySG

All codes: SG

Addresses

  • SG5 Tai Seng Avenue; #08-51; Hougang, North East Community Development Council 536671Primary

Grid intelligence Members

Funding

Last round · 21 November 2021US$ 78.2MSeries unknown · investor: SCI Group
Rounds1
Round typeSeries unknown · venture round
Amount (USD)78,200,000
Stage ranknot recorded
Investors named1
Since last round4 yr 2 mo

Funding

1 funding roundFunding timeline. Latest round 21 Nov 2021: Series unknown, US$ 78.2M.20162026Series unknownUS$ 78.2M1 round
Show as table
Rounds1
Axis2016 to 2026
Series unknown · 21 Nov 2021US$ 78.2M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Notify me about spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend
Notify me about signals

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
Notify me about financials

People & contacts

4 employee profiles on record · names withheld.

Counts only. No names are stored here, and none are served.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under BioSyngen?

One Singapore entity on ACRA. BIOSYNGEN PTE. LTD. (UEN 201618108R), high confidence.

How many people work at BioSyngen?

The record holds 19 counted staff profiles at January 2026. Its self-reported band sits above that count and is not published as a headcount.

Where does BioSyngen have offices?

One address on record, Singapore only. Primary: 5 Tai Seng Avenue, #08-51, Hougang, North East Community Development Council 536671.

Has BioSyngen raised funding?

One round. Latest 21 November 2021: Series unknown, US$78,200,000, investor SCI Group.

What does BioSyngen list as its specialties?

Six tags on the brand's own list, among them Cell Therapy, GMP Manufacturing and Solid Tumor.

Which companies are listed alongside BioSyngen?

Five peer profiles on record: Tikva Allocell Pte Ltd and SCG Cell Therapy.